“Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy”
In this second call, the TRANSCAN-3 network focusses on hard-to-treat-cancers (HTTC), i.e. those characterized by very poor prognosis (5-year survival rate<25%) and for which survival has not improved significantly over the last decades. The JTC 2022 aims to foster translational research tackling current clinical challenges, which include the inadequacy of standard diagnostic tools or established early detection methods in the general population, but also the inefficacy of available treatment options, due to intrinsic resistance and/or ineffective drug delivery.
The expected outcome of the call is to improve the efficacy of current diagnosis, prognosis and treatment of HTTC, through the development of novel personalized approaches based on a better understanding of the peculiarities of HTTC.
For further information, please visit our dedicated JTC 2022 Webpage or contact the JTC 2022 Joint Call Secretariat: firstname.lastname@example.org
|23 May 2022||Publication of the call|
|6 June 2022 at 16:00 (CEST)||Opening of the on-line submission system for pre-proposals|
|18 July 2022 at 12:00 (CEST)||Deadline for pre-proposal submission|
|3 November 2022||Communication of the results of the pre-proposal assessment and invitation for full-proposal stage|
|17 November 2022||Opening of the submission system for full proposals|
|15 December 2022 at 12:00 (CET)||Deadline for full-proposal submission|
|Expected for April 2023||Communication of the funding decisions to the applicants|
|September 2023||Expected project start (also subject to regional/national procedures)|